BeiGene is a biotechnology company that specializes in the development of drugs for cancer treatment. BeiGene has developed several pharmaceuticals, including tislelizumab, a checkpoint inhibitor, and zanubrutinib.
Company profile
Ticker
BGNE
Exchange
Website
CEO
John Oyler
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
B10 Health Technologies Private Limited • BeiGene Argentina S.R.L. • BeiGene AUS Pty Ltd • BeiGene Austria GmbH • BeiGene (Beijing) Co., Ltd. • BeiGene Belgium SRL • BeiGene Biologics Co., Ltd. • BeiGene Brasil Ltda. • BeiGene (Canada) ULC • BeiGene Chile Limitada ...
BGNE stock data
Latest filings (excl ownership)
8-K
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K
Departure of Directors or Certain Officers
20 Mar 24
8-K
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
15 Mar 24
8-K
Other Events
8 Mar 24
10-K
2023 FY
Annual report
26 Feb 24
8-K
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
26 Feb 24
8-K
BeiGene Welcomes Experienced Life Sciences Executive Olivier Brandicourt to Board of Directors
23 Jan 24
8-K
Other Events
8 Dec 23
UPLOAD
Letter from SEC
7 Dec 23
Transcripts
Latest ownership filings
4
JOHN OYLER
11 Apr 24
144
Notice of proposed sale of securities
9 Apr 24
3
Titus B. Ball
26 Mar 24
144
Notice of proposed sale of securities
26 Mar 24
4
JOHN OYLER
14 Mar 24
4
Donald W. Glazer
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
4
OLIVIER BRANDICOURT
4 Mar 24
4
Julia Aijun Wang
4 Mar 24
144
Notice of proposed sale of securities
29 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.08 bn | 3.08 bn | 3.08 bn | 3.08 bn | 3.08 bn | 3.08 bn |
Cash burn (monthly) | 113.56 mm | 93.30 mm | 44.66 mm | 107.71 mm | 26.05 mm | 104.50 mm |
Cash used (since last report) | 780.70 mm | 641.43 mm | 307.00 mm | 740.51 mm | 179.09 mm | 718.42 mm |
Cash remaining | 2.30 bn | 2.44 bn | 2.77 bn | 2.34 bn | 2.90 bn | 2.36 bn |
Runway (months of cash) | 20.3 | 26.1 | 62.1 | 21.7 | 111.4 | 22.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 194 |
Opened positions | 18 |
Closed positions | 27 |
Increased positions | 67 |
Reduced positions | 68 |
13F shares | Current |
---|---|
Total value | 8.43 tn |
Total shares | 316.16 mm |
Total puts | 49.60 k |
Total calls | 83.00 k |
Total put/call ratio | 0.6 |
Largest owners | Shares | Value |
---|---|---|
AMGN AMGEN | 236.25 mm | $0.00 |
CELG Celgene | 32.75 mm | $5.43 bn |
Baker Bros. Advisors | 11.67 mm | $2.10 tn |
Capital International Investors | 6.05 mm | $1.09 tn |
Hillhouse Capital Advisors | 5.18 mm | $931.17 bn |
Primecap Management | 5.01 mm | $900.92 bn |
Baillie Gifford & Co | 3.87 mm | $696.38 bn |
Temasek | 3.01 mm | $542.16 bn |
FMR | 2.35 mm | $423.19 bn |
T. Rowe Price | 1.75 mm | $315.54 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
11 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 147.7432 | 2,811 | 415.31 k | 0 |
11 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 146.816 | 4,265 | 626.17 k | 2,811 |
11 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 146.088 | 5,008 | 731.61 k | 7,076 |
10 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 150.85 | 60 | 9.05 k | 12,084 |
10 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 149.7931 | 2,641 | 395.60 k | 12,144 |
10 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 149.1539 | 12,501 | 1.86 mm | 14,785 |
10 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 148.3962 | 11,514 | 1.71 mm | 27,286 |
9 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 154.2084 | 7,924 | 1.22 mm | 38,800 |
9 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 153.472 | 2,734 | 419.59 k | 46,724 |
9 Apr 24 | Oyler John | American Depositary Shares | Sell | Dispose S | Yes | Yes | 152.2839 | 542 | 82.54 k | 49,458 |
News
Evaluating BeiGene: Insights From 6 Financial Analysts
24 Apr 24
TD Cowen Maintains Buy on BeiGene, Raises Price Target to $236
24 Apr 24
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $164.3
8 Apr 24
4 Analysts Assess BeiGene: What You Need To Know
27 Mar 24
Bernstein Maintains Market Perform on BeiGene, Lowers Price Target to $161
27 Mar 24
Press releases
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting
24 Apr 24
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 24
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy
14 Mar 24
Thinking about trading options or stock in NVIDIA, Tesla, Oracle, Broadcom, or Beigene?
13 Mar 24
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation
13 Mar 24